PCR Journal Club

The objective of this study was to validate standardised clinical criteria for BVD and evaluate its association with mortality and rehospitalisation, thereby guiding optimal valve selection in clinical practice.

This single-arm, double-blinded, core-laboratory adjudicated, prospective trial, conducted across four European centers between August 2019 and April 2022, investigates whether CCTA and FFR-CT are able to exclude hemodynamically significant coronary stenoses in patients with high-risk NSTE-ACS.

This study demonstrates that OCT-defined TCFA is a superior prognostic marker compared to μQFR for assessing NCLs in AMI patients.

The authors hypothesized that enriching invasive coronary angiography (ICA) with an advanced invasive diagnosis (AID) strategy would increase the diagnostic yield of obstructive and non-obstructive coronary artery disease (INOCA).

NIRS-IVUS offers precise assessment of coronary artery pathology but is invasive and limited in scope, while CCTA is emerging as a non-invasive alternative for comprehensive plaque evaluation.

The AD-HOC Registry aimed to evaluate procedural success and clinical outcomes of current-generation BEVs and SEVs in treating stenotic Sievers type 1 BAV.

The post-hoc analysis found that quantitative flow ratio (QFR)-based deferral of coronary artery revascularisation resulted in a higher incidence of 1-year major adverse cardiac events (MACE) as compared with fractional flow reserve (FFR)-based deferral.

This registry-based observational study compares surgical and percutaneous revascularization in patients with multivessel disease who underwent treatment for non-ST-segment elevation myocardial infarction (NSTEMI), utilizing data extracted from the SWEDEHEART registry.

The TCW trial found that FFR-guided PCI with TAVI offers favorable one-year outcomes, including lower rates of all-cause mortality, MI, disabling stroke, revascularisation, valve reintervention, and severe bleeding, compared to CABG with SAVR.

The present study compares a novel sirolimus-coated balloon with a clinically proven paclitaxel-coated balloon for the treatment of de novo coronary lesions, demonstrating non-inferiority in terms of angiographic late lumen loss at 6 months.